EG BioMed Officially Launches Nationwide Telehealth Platform, Delivering an End-to-End Cancer Testing Ecosystem

EG BioMed US Inc. has officially launched the EG Telehealth Platform (MDI), integrating a nationwide physician network, telemedicine services, mobile phlebotomy, and its CLIA-certified and CAP-accredited clinical laboratory into a comprehensive one-stop cancer testing platform. The platform streamlines the entire testing journey—from online appointment scheduling, physician consultation, and test ordering to specimen collection, laboratory analysis, and digital report delivery—providing patients with convenient access to precision healthcare while supporting partners in expanding into the U.S. market.

Now fully operational across 47 U.S. states, the EG Telehealth Platform delivers compliant telemedicine services through a nationwide network of licensed physicians. By removing geographical barriers to cancer testing, the platform creates a scalable digital healthcare model that significantly improves accessibility and patient convenience.

At the core of the platform is EG BioMed's CLIA-certified and CAP-accredited clinical laboratory, located in the Greater Seattle area of Washington State. The laboratory provides high-quality molecular diagnostics, nucleic acid and protein analysis, while supporting LDT (Laboratory Developed Test) development, product validation, clinical research, and regulatory implementation. Through its Shared Laboratory Program, EG BioMed also offers advanced laboratory infrastructure and technical support to accelerate product development and commercialization.

Unlike traditional laboratory-only services, the EG Telehealth Platform delivers a fully integrated precision healthcare ecosystem by connecting physicians, patients, laboratory testing, and industry partners. The platform provides end-to-end services including online test ordering, telemedicine consultations, physician evaluation, mobile phlebotomy, CLIA/CAP-certified laboratory testing, digital reporting, and follow-up health management.

By integrating every step of the patient journey into a single platform, EG BioMed delivers a true end-to-end solution that improves patient access while enabling biotechnology companies, diagnostic developers, and healthcare partners to accelerate clinical research, commercialize innovative diagnostic technologies, and expand across the U.S. market.